Shield Therapeutics' ST10 Delivers Robust Results Meeting both Primary and Secondary Endpoints in the Pivotal AEGIS Phase 3 Programme for the Treatment of Iron Deficiency Anaemia in Inflammatory Bowel Disease

Shield Therapeutics' ST10 DeliversShield Therapeutics' ST10 Delivers Robust Results Meeting both Primary and Secondary Endpoints in the Pivotal AEGIS Phase 3 Programme for the Treatment of Iron Deficiency Anaemia in IInnffllaammmmaattoorryy BBoowweell DDiisseeaassee PR Newswire LONDON, January 7, 2014 ~ ST10 strongly demonstrates potential to be (1) the only effective oral treatment for ferrous intolerant IDA patients and (2) an effective alternative to intravenous iron treatment ~ Shield Therapeutics (Shield), an independent specialty pharmaceutical company focused on the development of mineral-derived hospital pharmaceuticals, today announces strongly positive top-line data from the pivotal Phase 3 programme of ST10 for the treatment of iron deficiency anaemia (IDA) in inflammatory bowel disease (IBD). ST10, a novel orally-dosed form of ferric iron, delivered a mean improvement in haemoglobin levels of 2.